iRadimed Affirms FY2026 Adj EPS Guidance of $2.06-$2.21 vs $2.08 Est; Affirms FY2026 Sales Guidance of $91.000M-$96.000M vs $92.346M Est

Benzinga Newsdesk www.benzinga.com Neutral 60.3%

Neg 0% Neu 60.3% Pos 0%

iRadimed (NASDAQ:IRMD) affirms FY2026 Adj EPS guidance from $2.06-$2.21 to $2.06-$2.21 vs $2.08 analyst estimate. Affirms FY2026 sales outlook from $91.000 million-$96.000 million to $91.000 million-$96.000 million vs $92.346 million estimate.